Immunohistochemistry shows that overexpression of cell division cycle associated 8 (CDCA8) and AURKB can result in bad outcome of lung cancer patients; thus, suppression of the CDCA8-AURKB pathway is a potential therapeutic strategy for lung cancer [38]. Here, AURKB is linked to lung carcinoma.